hig.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Differences in trial knowledge and motives for participation among cancer patients in phase 3 clinical trials
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet, Centrum för forsknings- och bioetik.
Uppsala universitet; University of Bergen, Bergen, Norway.
Uppsala universitet, Vårdvetenskap.ORCID iD: 0000-0002-9457-9521
Show others and affiliations
2015 (English)In: European Journal of Cancer Care, ISSN 0961-5423, E-ISSN 1365-2354, Vol. 25, no 3, p. 516-523Article in journal (Refereed) Published
Abstract [en]

While participants in clinical oncology trials are essential for the advancement of cancer therapies, factors decisive for patient participation have been described but need further investigation, particularly in the case of phase 3 studies. The aim of this study was to investigate differences in trial knowledge and motives for participation in phase 3 clinical cancer trials in relation to gender, age, education levels and former trial experience. The results of a questionnaire returned from 88 of 96 patients (92%) were analysed using the Mann-Whitney U-test. There were small, barely relevant differences in trial knowledge among patients when stratified by gender, age or education. Participants with former trial experience were less aware about the right to withdraw. Male participants and those aged ≥65 years were significantly more motivated by a feeling of duty, or by the opinions of close ones. Men seem more motivated than women by external factors. With the awareness that elderly and single male participants might be a vulnerable group and participants with former trial experience are less likely to be sufficiently informed, the information consent process should focus more on these patients. We conclude that the informed consent process seems to work well, with good results within most subgroups.

Place, publisher, year, edition, pages
2015. Vol. 25, no 3, p. 516-523
Keywords [en]
adults, cancer, clinical trials, patient education, patient information, phase 3 trials
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:hig:diva-20510DOI: 10.1111/ecc.12319ISI: 000375066900018PubMedID: 25904313Scopus ID: 2-s2.0-84928316987OAI: oai:DiVA.org:hig-20510DiVA, id: diva2:865754
Available from: 2015-05-08 Created: 2015-10-29 Last updated: 2022-09-20Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Silén, Marit

Search in DiVA

By author/editor
Silén, Marit
In the same journal
European Journal of Cancer Care
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 604 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard-cite-them-right
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • sv-SE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • de-DE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf